Histone methylases as novel drug targets: Developing inhibitors of EZH2

Future Medicinal Chemistry

Volumn 6, Issue 17, 2014, Pages 1943-1965

  Baugé, Catherine ^a,b   Bazille, Céline ^a,b,c   Girard, Nicolas ^a,b   Lhuissier, Eva ^a,b   Boumediene, Karim ^a,b  

^a NORMANDIE UNIVERSITÉ   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; ARGININE; EI 1; EPZ 005687; EPZ 6438; GSK 126; GSK 343; HISTONE DEMETHYLASE; HISTONE H3; HISTONE H4; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; HISTONE METHYLTRANSFERASE; LYSINE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN SWI; TRANSCRIPTION FACTOR EZH2; UNC 1999; UNCLASSIFIED DRUG; ENZYME INHIBITOR; HISTONE; MOLECULAR LIBRARY; PROTEIN BINDING;

ALPHA HELIX; B CELL LYMPHOMA; CELL FATE; EPIGENETICS; GENE MUTATION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; IMMUNE SYSTEM; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; STEM CELL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MOLECULAR LIBRARY; PROTEIN TERTIARY STRUCTURE;

CELLULAR REPROGRAMMING; ENZYME INHIBITORS; EPIGENOMICS; HISTONES; HUMANS; POLYCOMB REPRESSIVE COMPLEX 2; POLYMORPHISM, GENETIC; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SMALL MOLECULE LIBRARIES;

EID: 84919819078     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.123     Document Type: Review

References (159)

1. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 403(6765), 41-45 (2000
2. Marks H, Kalkan T, Menafra R et al. The transcriptional and epigenomic foundations of ground state pluripotency. Cell 149(3), 590-604 (2012
3. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 21(3), 381-395 (2011
4. Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell 48(4), 491-507 (2012
5. Tan M, Luo H, Lee S et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146(6), 1016-1028 (2011
6. Wozniak GG, Strahl BD. Hitting the "mark": interpreting lysine methylation in the context of active transcription. Biochim. Biophys. Acta doi:10.1016/j.bbagrm.2014.03.002 (2014) (Epub ahead of print
7. Berger SL. The complex language of chromatin regulation during transcription. Nature 447(7143), 407-412 (2007
8. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14(11), 1025-1040 (2007
9. Bernstein BE, Kamal M, Lindblad-Toh K et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120(2), 169-181 (2005
10. Schubeler D, MacAlpine DM, Scalzo D et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 18(11), 1263-1271 (2004
11. Pokholok DK, Harbison CT, Levine S et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122(4), 517-527 (2005
12. Santos-Rosa H, Schneider R, Bannister AJ et al. Active genes are tri-methylated at K4 of histone H3. Nature 419(6905), 407-411 (2002
13. Strahl BD, Ohba R, Cook RG, Allis CD. Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc. Natl Acad. Sci. USA 96(26), 14967-14972 (1999
14. Rao B, Shibata Y, Strahl BD, Lieb JD. Dimethylation of histone H3 at lysine 36 demarcates regulatory and nonregulatory chromatin genome-wide. Mol. Cell. Biol. 25(21), 9447-9459 (2005
15. Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nat. Rev. Mol. Cell. Biol. 13(2), 115-126 (2012
16. Lee J-S, Shilatifard A. A site to remember: H3K36 methylation a mark for histone deacetylation. Mutat. Res. 618(1-2), 130-134 (2007
17. Lehnertz B, Ueda Y, Derijck AAHA et al. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr. Biol. 13(14), 1192-1200 (2003
18. Rougeulle C, Chaumeil J, Sarma K et al. Differential histone H3 Lys-9 and Lys-27 methylation profiles on the X chromosome. Mol. Cell. Biol. 24(12), 5475-5484 (2004
19. Escamilla-Del-Arenal M, da Rocha ST, Spruijt CG et al. Cdyl, a new partner of the inactive X chromosome and potential reader of H3K27me3 and H3K9me2. Mol. Cell. Biol. 33(24), 5005-5020 (2013
20. Molina-Serrano D, Schiza V, Kirmizis A. Cross-talk among epigenetic modifications: lessons from histone arginine methylation. Biochem. Soc. Trans. 41(3), 751-759 (2013
21. Migliori V, Phalke S, Bezzi M, Guccione E. Arginine/lysinemethyl/methyl switches: biochemical role of histone arginine methylation in transcriptional regulation. Epigenomics 2(1), 119-137 (2010
22. Lorenzo AD, Bedford MT. Histone arginine methylation. FEBS Lett. 585(13), 2024-2031 (2011
23. Petrossian TC, Clarke SG. Uncovering the human methyltransferasome. Mol. Cell Proteomics 10(1), M110.000976 (2011
24. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13(5), 343-357 (2012
25. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell. Biol. 13(5), 297-311 (2012
26. Hublitz P, Albert M, Peters AHFM. Mechanisms of transcriptional repression by histone lysine methylation. Int. J. Dev. Biol. 53(2-3), 335-354 (2009
27. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22(20), 5323-5335 (2003
28. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624-629 (2002
29. Collett K, Eide GE, Arnes J et al. Expression of enhancer of zeste homolog 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 12(4), 1168-1174 (2006
30. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24(2), 268-273 (2006
31. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100(20), 11606-11611 (2003
32. Weikert S, Christoph F, Köllermann J et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 16(2), 349-353 (2005
33. Albert M, Helin K. Histone methyltransferases in cancer. Semin. Cell Dev. Biol. 21(2), 209-220 (2010
34. Agger K, Christensen J, Cloos PAC, Helin K. The emerging functions of histone demethylases. Curr. Opin. Genet. Dev. 18(2), 159-168 (2008
35. Kirmizis A, Bartley SM, Kuzmichev A et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18(13), 1592-1605 (2004
36. Xu K, Wu ZJ, Groner AC et al. EZH2 oncogenic activity in castration resistant prostate cancer cells is polycombindependent. Science 338(6113), 1465-1469 (2012
37. Kim E, Kim M, Woo D-H et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23(6), 839-852 (2013
38. Kogure M, Takawa M, Saloura V et al. The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination. Neoplasia 15(11), 1251-1261 (2013
39. Chu C-S, Lo P-W, Yeh Y-H et al. O-GlcNAcylation regulates EZH2 protein stability and function. Proc. Natl Acad. Sci. USA 111(4), 1355-1360 (2014
40. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15(1), 57-67 (2004
41. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 23(20), 4061-4071 (2004
42. Sewalt RG, van Der Vlag J, Gunster MJ et al. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol. Cell. Biol. 18(6), 3586-3595 (1998
43. Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K. Point mutations in the WD40 domain of EED block its interaction with EZH2. Mol. Cell. Biol. 18(10), 5634-5642 (1998
44. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 469(7330), 343-349 (2011
45. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12(9), 599-612 (2012
46. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6(11), 846-856 (2006
47. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T. The polycomb-group gene EZH2 is required for early mouse development. Mol. Cell. Biol. 21(13), 4330-4336 (2001
48. Shen X, Liu Y, Hsu Y-J et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32(4), 491-502 (2008
49. Pereira CF, Piccolo FM, Tsubouchi T et al. ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency. Cell Stem Cell 6(6), 547-556 (2010
50. Zhang M, Wang F, Kou Z, Zhang Y, Gao S. Defective chromatin structure in somatic cell cloned mouse embryos. J. Biol. Chem. 284(37), 24981-24987 (2009
51. Villasante A, Piazzolla D, Li H, Gomez-Lopez G, Djabali M, Serrano M. Epigenetic regulation of Nanog expression by EZH2 in pluripotent stem cells. Cell Cycle 10(9), 1488-1498 (2011
52. Ding X, Wang X, Sontag S et al. The polycomb protein EZH2 impacts on iPS cell generation. Stem Cells Dev. 23(9), 931-940 (2013
53. Neri F, Zippo A, Krepelova A, Cherubini A, Rocchigiani M, Oliviero S. Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. Mol. Cell. Biol. 32(4), 840-851 (2012
54. Fragola G, Germain P-L, Laise P et al. Cell reprogramming requires silencing of a core subset of polycomb targets. PLoS Genet. 9(2), e1003292 (2013
55. Müller J, Hart CM, Francis NJ et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111(2), 197-208 (2002
56. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111(2), 185-196 (2002
57. Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298(5595), 1039-1043 (2002
58. Kuzmichev A, Jenuwein T, Tempst P, Reinberg D Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol. Cell 14(2), 183-193 (2004
59. Chen Y-H, Hung M-C, Li L-Y. EZH2: a pivotal regulator in controlling cell differentiation. Am. J. Transl Res. 4(4), 364-375 (2012
60. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb EZH2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 18(21), 2627-2638 (2004
61. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Mir-214-dependent regulation of the polycomb protein EZH2 in skeletal muscle and embryonic stem cells. Mol. Cell 36(1), 61-74 (2009
62. Wong CF, Tellam RL. MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J. Biol. Chem. 283(15), 9836-9843 (2008
63. Palacios D, Mozzetta C, Consalvi S et al. TNF/p38?/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 7(4), 455-469 (2010
64. Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle 11(20), 3828-3836 (2012
65. Woodhouse S, Pugazhendhi D, Brien P, Pell JM. EZH2 maintains a key phase of muscle satellite cell expansion but does not regulate terminal differentiation. J. Cell Sci. 126(Pt 2), 565-579 (2013
66. Juan AH, Derfoul A, Feng X et al. Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Genes Dev. 25(8), 789-794 (2011
67. Acharyya S, Sharma SM, Cheng AS et al. TNF inhibits notch-1 in skeletal muscle cells by EZH2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS ONE 5(8), e12479 (2010
68. Wei Y, Chen Y-H, Li L-Y et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 13(1), 87-94 (2011
69. Wu H, Whitfield TW, Gordon JA et al. Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis. Genome Biol. 15(3), R52 (2014
70. Wang L, Jin Q, Lee J-E, Su I, Ge K. Histone H3K27 methyltransferase EZH2 represses Wnt genes to facilitate adipogenesis. Proc. Natl Acad. Sci. USA 107(16), 7317-7322 (2010
71. Hobert O, Sures I, Ciossek T, Fuchs M, Ullrich A. Isolation and developmental expression analysis of Enx-1, a novel mouse Polycomb group gene. Mech. Dev. 55(2), 171-184 (1996
72. Raaphorst FM, van Kemenade FJ, Blokzijl T et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am. J. Pathol. 157(3), 709-715 (2000
73. Fukuyama T, Otsuka T, Shigematsu H et al. Proliferative involvement of ENX-1, a putative human polycomb group gene, in haematopoietic cells. Br. J. Haematol. 108(4), 842-847 (2000
74. Hobert O, Jallal B, Ullrich A. Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol. Cell. Biol. 16(6), 3066-3073 (1996
75. Su I-H, Basavaraj A, Krutchinsky AN et al. EZH2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4(2), 124-131 (2003
76. Beguelin W, Popovic R, Teater M et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23(5), 677-692 (2013
77. Tumes DJ, Onodera A, Suzuki A et al. The polycomb protein EZH2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells. Immunity 39(5), 819-832 (2013
78. Raaphorst FM, Meijer CJLM, Fieret E et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5(6), 481-488 (2003
79. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007
80. Suv' M-L, Riggi N, Janiszewska M et al. EZH2 Is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69(24), 9211-9218 (2009
81. Kodach LL, Jacobs RJ, Heijmans J et al. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 31(9), 1567-1575 (2010
82. Takawa M, Masuda K, Kunizaki M et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102(7), 1298-1305 (2011
83. Varambally S, Cao Q, Mani R-S et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695-1699 (2008
84. Wagener N, Macher-Goeppinger S, Pritsch M et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10, 524 (2010
85. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24(41), 6269-6280 (2005
86. Yu J, Yu J, Rhodes DR et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67(22), 10657-10663 (2007
87. Chase A, Cross NCP. Aberrations of EZH2 in cancer. Clin. Cancer Res. 17(9), 2613-2618 (2011
88. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647(1-2), 21-29 (2008
89. Velichutina I, Shaknovich R, Geng H et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116(24), 5247-5255 (2010
90. Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor - a marker or mover of metastatic prostate cancer?. Cancer Cell 2(5), 349-350 (2002
91. Girard N, Bazille C, Lhuissier E et al. 3-deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells. PLoS ONE 9(5), e98176 (2014
92. Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod. Pathol. 24(6), 786-793 (2011
93. McCabe MT, Graves AP, Ganji G et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109(8), 2989-2994 (2012
94. Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360), 298-303 (2011
95. Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43(9), 830-837 (2011
96. Sneeringer CJ, Scott MP, Kuntz KW et al. Coordinated activities of wild-type plus mutant EZH2 drive tumorassociated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107(49), 20980-20985 (2010).
97. Wigle TJ, Knutson SK, Jin L et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 585(19), 3011-3014 (2011
98. Yap DB, Chu J, Berg T et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117(8), 2451-2459 (2011
99. McCabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427), 108-112 (2012
100. Bödör C, Grossmann V, Popov N et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122(18), 3165-3168 (2013
101. Bödör C, O'Riain C, Wrench D et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 25(4), 726-729 (2011
102. Majer CR, Jin L, Scott MP et al. A687V EZH2 is a gain-offunction mutation found in lymphoma patients. FEBS Lett. 586(19), 3448-3451 (2012
103. Lee HJ, Shin DH, Kim KB et al. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk. Lymphoma 55(9), 2056-2063 (2014
104. Li Z, Xu L, Tang N et al. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. FEBS Lett. 588(17), 3000-3300 (2014
105. Nikoloski G, Langemeijer SMC, Kuiper RP et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42(8), 665-667 (2010
106. Chen X, Song N, Matsumoto K et al. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer. Int. J. Oncol. 43(5), 1467-1480 (2013
107. Wei Y, Xia W, Zhang Z et al. Loss of trimethylation at lysine 27 of histone H3 Is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47(9), 701-706 (2008
108. Chang C-J, Hung M-C. The role of EZH2 in tumour progression. Br. J. Cancer 106(2), 243-247 (2012
109. Zhong J, Min L, Huang H et al. EZH2 regulates the expression of p16 in the nasopharyngeal cancer cells. Technol. Cancer Res. Treat. 12(3), 269-274 (2013
110. Kheradmand Kia S, Solaimani Kartalaei P, Farahbakhshian E, Pourfarzad F, von Lindern M, Verrijzer CP. EZH2-dependent chromatin looping controls INK4a and INK4b, but not ARF, during human progenitor cell differentiation and cellular senescence. Epigenetics Chromatin 2(1), 16 (2009
111. Ferraro A, Mourtzoukou D, Kosmidou V et al. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control epithelial-mesenchymal transition and anoikis in colon cancer cells. Int. J. Biochem. Cell Biol. 45(2), 243-254 (2013
112. Smits M, Nilsson J, Mir SE et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8), 710-720 (2011
113. Shin YJ, Kim J-H. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS ONE 7(1), e30393 (2012
114. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase EZH2. Clin. Cancer Res. 14(21), 6790-6796 (2008
115. Zhang Y, Liu G, Lin C, Liao G, Tang B. Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sci. 92(17-19), 896-902 (2013
116. Hu S, Yu L, Li Z et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol. Ther. 10(8), 788-795 (2010
117. Lee ST, Li Z, Wu Z et al. Context-specific regulation of NF-?B target gene expression by EZH2 in breast cancers. Mol. Cell 43(5), 798-810 (2011
118. Shi B, Liang J, Yang X et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell. Biol. 27(14), 5105-5119 (2007
119. Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11(7), 481-492 (2011
120. Shao Z, Raible F, Mollaaghababa R et al. Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 98(1), 37-46 (1999
121. Francis NJ, Saurin AJ, Shao Z, Kingston RE. Reconstitution of a functional core polycomb repressive complex. Mol. Cell 8(3), 545-556 (2001
122. Kennison JA, Tamkun JW. Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila. Proc. Natl Acad. Sci. USA 85(21), 8136-8140 (1988
123. Tamkun JW, Deuring R, Scott MP et al. Brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 68(3), 561-572 (1992
124. Kennison JA. The Polycomb and trithorax group proteins of Drosophila: Trans-regulators of homeotic gene function. Annu. Rev. Genet. 29, 289-303 (1995
125. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol. Cell. Biol. 28(10), 3457-3464 (2008
126. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 8(1), e55119 (2013
127. Versteege I, Sévenet N, Lange J et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394(6689), 203-206 (1998
128. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl Acad. Sci. USA 97(25), 13796-13800 (2000
129. Wilson BG, Wang X, Shen X et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18(4), 316-328 (2010
130. Verma SK, Knight SD. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer. Future Med. Chem. 5(14), 1661-1670 (2013
131. Miranda TB, Cortez CC, Yoo CB et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8(6), 1579-1588 (2009
132. Fiskus W, Wang Y, Sreekumar A et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114(13), 2733-2743 (2009
133. Xie Z, Bi C, Cheong LL et al. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS ONE 6(6), e21583 (2011
134. Chiba T, Suzuki E, Negishi M et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int. J. Cancer 130(11), 2557-2567 (2012
135. Van Aller GS, Pappalardi MB, Ott HM et al. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem. Biol. 9(3), 622-629 (2014
136. Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 12(13), 2113-2119 (2013
137. Verma SK, Tian X, LaFrance LV et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 3(12), 1091-1096 (2012
138. Knutson SK, Wigle TJ, Warholic NM et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8(11), 890-896 (2012
139. Knutson SK, Kawano S, Minoshima Y et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13(4), 842-854 (2014
140. Qi W, Chan H, Teng L et al. Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109(52), 21360-21365 (2012
141. Konze KD, Ma A, Li F et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8(6), 1324-1334 (2013
142. Kim W, Bird GH, Neff T et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 9(10), 643-650 (2013
143. Glazer RI, Hartman KD, Knode MC et al. 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem. Biophys. Res. Commun. 135(2), 688-694 (1986
144. Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyll-homocysteine hydrolase inhibitor. Antiviral Res. 45(2), 135-147 (2000
145. Kikuchi J, Takashina T, Kinoshita I et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 78(2), 138-143 (2012
146. Cheng LL, Itahana Y, Lei ZD et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin. Cancer Res. 18(15), 4201-4212 (2012
147. Fiskus W, Rao R, Balusu R et al. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin. Cancer Res. 18(22), 6227-6238 (2012
148. Benoit YD, Witherspoon MS, Laursen KB et al. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp. Cell Res. 319(10), 1463-1470 (2013
149. Li Z, Wang Y, Qiu J et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget 4(12), 2532-2549 (2013
150. Liu L, Xu Z, Zhong L et al. EZH2 promotes tumor cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. doi:10.1111bju.12702 (2014) (Epub ahead of print
151. He S, Wang J, Kato K et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood 119(5), 1274-1282 (2012
152. Fujiwara T, Saitoh H, Inoue A et al. 3-Deazaneplanocin A (DZNep), an inhibitor of s-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation. J. Biol. Chem. 289(12), 8121-8134 (2014
153. Tan J, Yan Y, Wang X, Jiang Y, Xu HE. EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol. Sin. 35(2), 161-174 (2014
154. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8(9), 724-732 (2009
155. Crea F, Hurt EM, Mathews LA et al. Pharmacologic disruption of Polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol. Cancer. 10, 40 (2011
156. Chen Y, Lin MC, Yao H et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatol. Baltim. Md. 46(1), 200-208 (2007
157. Crea F, Fornaro L, Bocci G et al. EZH2 inhibition: Targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 31(3-4), 753-761 (2012
158. Vella S, Gnani D, Crudele A et al. EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD. Int. J. Mol. Sci. 14(12), 24154-24168 (2013
159. Su IH, Basavaraj A, Krutchinsky AN, et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4(2), 124-131 (2003